Progressive Multifocal Leukoencephalopathy (PML2013)
|Event Date/Time: Jun 19, 2013||End Date/Time: Jun 20, 2013|
|Registration Date: Jun 19, 2013|
|Early Registration Date: May 13, 2013|
|Abstract Submission Date: Apr 29, 2013|
Progressive Multifocal Leukoencephalopathy (PML) is, in the general population, a rare but serious demyelinating disease of the brain, often resulting in severe disability or death and is caused by infection of oligodendrocytes by the JC polyomavirus (JCV). It is believed that fifty to sixty percent of the population is sero-positive for JCV, indicating exposure to the virus. Despite the high prevalence of JCV infection in the human population, which typically leads to a chronic, asymptomatic infection, incidence of PML in the general population is very low. The pathogenesis of PML is not well understood. It is believed that the development of PML, while dependent on the presence of JCV, is the result of a confluence of viral and host risk factors, which may include an altered or compromised immune system such as in individuals with HIV-1 infection/acquired immune deficiency syndrome (AIDS), or patients undergoing chronic immunosuppressive therapies after organ transplantation, for treatment of lymphomas, or for autoimmune conditions, such as MS.
This 2-day conference will bring together basic science researchers, clinicians, physicians, epidemiologists, and regulatory experts from academia, industry, and government to address novel issues, current challenges, and future directions of basic and clinical research relevant to the mitigation, potential future cure, and risk stratification of PML. Topics of discussion will include JCV virology, PML pathogenesis, risk stratification and disease diagnosis and management. The meeting will feature a series of plenary lectures, short talk presentations selected from submitted abstracts, a poster session, and a closing panel discussion.
Call for Abstracts:
The deadline for poster abstract submission is Monday, April 29, 2013.
Select poster abstracts will be chosen for short oral presentations. For complete abstract submission instructions, please send an email to with "Abstract Information" in the subject line. There is no need to type a message; instructions will be forwarded automatically. Please call 212.298.8696 with any questions.
Call for Travel Fellowship Applications:
The deadline for submission of applications is Monday, April 29, 2013.
A small number of fellowships will be made available to qualified graduate students, postdoctoral fellows, and early-career investigators demonstrating significant contributions to the field. For detailed information on eligibility and application instructions, please send an email to with the words "Grant Information" in the subject line. There is no need to type a message; instructions will be forwarded automatically. Please call 212.298.8696 with any questions.
Conference Planning Committee
Claudio Carini, MD, Pfizer Inc.
Teresa Compton, PhD, Biogen Idec (Conference Chair)
Marion Kasaian, PhD, Pfizer Inc.
Theodora Salcedo, PhD, Bristol-Myers Squibb Company
Anne Vogt, PhD, F. Hoffmann-La Roche Ltd
Scientific Advisory Board
Leonard Calabrese, DO, Cleveland Clinic
Paola Cinque, MD, PhD, San Raffaele Scientific Institute, Milan
David Clifford, MD, Washington University School of Medicine
Robert Garcea, MD, University of Colorado, Boulder
Gene Major, PhD, National Institute of Neurological Disorders and Stroke
Kenneth Tyler, MD, University of Colorado School of Medicine
Thomas Weber, MD, Marienkrankenhaus Hamburg